Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.1003556860000*세트로렐릭스동결건조물의제조방법
KR 25.09.2002
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Appl.No 1019940002771 Applicant Inventor 위르겐엥겔
본 발명은 신규한 동결건조물 및 이의 제조방법외에 여성 불임증의 치료 및 생식선을 보호하기 위한 동결건조물의 용도에 관한 것이다.
2.0947200Compositions comprising Cetrorelix acetate for the treatment of female infertility and gonadal protection
EP 06.10.1999
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
Appl.No 99102340 Applicant ZENTARIS IVF GMBH Inventor ENGEL JÜRGEN PROF DR
Sterile freeze-dried cetrorelix acetate (a peptide described in EP299402) is used in the treatment of female infertility. Independent claims are also included for the following: (1) use of sterile freeze-dried cetrorelix acetate for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy; (2) a composition comprising sterile freeze-dried cetrorelix acetate and optionally excipients for use in the treatment of female infertility; (3) a composition comprising sterile freeze-dried cetrorelix acetate and optionally excipients for protecting gonads against noxious agents that damage germ cells, e.g. radiation treatment and chemotherapy with cytostatic agents.
3.20200062839USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH VEGF INHIBITORS TO TREAT CANCER
US 27.02.2020
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
Appl.No 16609721 Applicant DEL MAR PHARMACEUTICALS (BC) LTD. Inventor Jeffrey A. BACHA

Methods and compositions employing dianhydrogalactitol or a derivative or analog of dianhydrogalactitol together with a vascular endothelial growth factor (VEGF) inhibitor or other anti-neoplastic agents can be used for treatment of glioma. In particular, methods and compositions according to the invention can decrease the invasiveness of gliomas. Further disclosed are methods of using the compositions for treating a malignancy that has failed a VEGF inhibitor treatment.

4.6716817Method of treatment of female infertility
US 06.04.2004
Int.Class A01N 43/60
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
43Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
48having rings with two nitrogen atoms as the only ring hetero atoms
601,4-Diazines; Hydrogenated 1,4-diazines
Appl.No 09233468 Applicant Zentaris AG Inventor Engel, Jürgen

A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.

5.20020099018Oligopeptide lyophilisate, their preparation and use
US 25.07.2002
Int.Class A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No 08468145 Applicant Zentaris GmbH Inventor Engel, Jürgen

A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.

6.02372401EUKARYOTIC HOST CELL FOR EXPRESSION VITAMIN K DEPENDENT PROTEIN, EXPRESSION VECTOR IN EUKARYOTIC CELLS, METHOD FOR MAKING GAMMA-CARBOXYLATED VITAMIN K DEPENDENT PROTEIN AND METHOD FOR MAKING PHARMACEUTICAL COMPOSITION FOR COAGULATION INDUCTION OR STIMULATION OF COAGULATION INCREASE OR DECREASE
RU 10.11.2009
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Appl.No 2006110147/13 Applicant Inventor ФЕНГЕ Кристель (SE)
FIELD: medicine. SUBSTANCE: vitamin K dependent protein is made by separating a cultivated eukaryotic cell that contains an expressing vector that contains a nucleic acid molecule coding vitamin K dependent protein and associated sequences regulating expression. The associated sequences contain the first promoter and the nucleic acid molecule coding gamma-glutamylcarboxylase, and the second promoter. The first promoter represents a pre-early promoter of human cytomegalovirus (hCMV), and the second promoter is a pre-early promoter SV40. Herewith the expressing relation of vitamin K dependent protein and gamma-glutamylcarboxylase is 10:1 to 250:1. EFFECT: invention allows for making gamma-carboxylated vitamin K dependent protein in production quantities. 29 cl, 5 dwg, 6 tbl, 7 ex
7.WO/2024/168093SUPER-RESOLUTION MICROSCOPY (SRM) MULTIPLEXING WITH CLEAVABLE MOIETIES
WO 15.08.2024
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No PCT/US2024/014894 Applicant TOREADOR THERAPEUTICS, INC. Inventor GUENOT, Jeanmarie
Described herein are methods of providing a super-resolution microscopy (SRM) image of a target molecule expressed on cell surfaces of a cell sample. Further disclosed herein are methods of providing multiplexed SRM images of a number of different target molecules expressed on cell surfaces of a cell sample.
8.20090305975Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection
US 10.12.2009
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No 12226491 Applicant Inventor Yang Guang

Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.

9.WO/2006/029005PROMOTER SUBSTITUTION FOR IMMUNOGLOBULIN THERAPY
WO 16.03.2006
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
Appl.No PCT/US2005/031397 Applicant OKLAHOMA MEDICAL RESEARCH FOUNDATION Inventor WEBB, Carol, F.
The present invention involves the identification of Bright as involved in immunoglobulin production, and the targeting of that function for the treatment of disease states associated with pathologic immunoglobulin production. Also provided are methods of identifying candidate substances with Bright-inhibitory activity.
10.0249223NOVEL ANTIHYPERTENSIVE AGENT
EP 16.12.1987
Int.Class C07D 513/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 87108410 Applicant MERRELL DOW PHARMACEUTICALS INC. Inventor FLYNN, GARY A.
This invention relates to derivatives of fused tricyclic lactams, of the formula: to the intermediates and processes useful for their preparation and to their pharmacological effect in inhibiting the angiotensin converting enzyme and to their end-use application in the treatment of hypertension.